Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina

• Published in: Biomolecules & Biomedicine Vol. 24; no. 5; pp. 1400 - 1406
• Main Authors: Salkić, Nermin, Bašić Denjagić, Mirela, Zubčević, Nađa, Tamburić, Renata, Husić Selimović, Azra, Babić, Emil, Bevanda, Milenko, Saray, Aida, Jovanović, Predrag, Tošić, Zoran, Dobrovoljski, Aleksandar, Barać, Tatjana
• Format: Journal Article
• Language: English
• Published: Bosnia and Herzegovina Association of Basic Medical Sciences 01.10.2024; Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
• Subjects: Adult; Analysis; Antibodies, Monoclonal, Humanized - therapeutic use; Bosnia and Herzegovina; Care and treatment; Colitis, Ulcerative - drug therapy; Composition; Crohn Disease - drug therapy; Crohn's disease (CD); Diagnosis; Female; Gastrointestinal Agents - therapeutic use; Humans; Immune response; Inflammatory bowel disease (IBD); Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Male; Microbiota (Symbiotic organisms); Middle Aged; real-world efficacy; Retrospective Studies; Treatment Outcome; ulcerative colitis (UC); vedolizumab; Bosnia and Herzegovina
• ISSN: 2831-0896; 2831-090X; 2831-090X
• DOI: 10.17305/bb.2024.10433

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management.